IRCT20230222057500N1
Recruiting
Phase 1
Cell therapy with use of mesenchymal stem cells in infertile women with Thin Endometrium
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Tehran University of Medical Sciences
- Enrollment
- 10
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Infertile women with thin endometrium
- •patient with thin endometrium for whom drugs and other treatments were ineffective
- •Endometrial thickness less than 7 mm
- •Embryo transfer is cancelled because of thin endometrium
- •Age between 20 and 44 years
- •HBsAg negative, HCV negative, HIV negative, CMV negative
Exclusion Criteria
- •Abnormal karyotype
- •Contraindications to hormone replacement therapy
- •Systemic diseases such as hypertension, diabetes
- •Other uterine diseases including uterine malformations, large myoma, endometrial tuberculosis, endometriosis
- •Autoimmune diseases such as rheumatoid arthritis, lupus
- •Unable to adhere to the follow\-up
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Infusion of mesenchymal stem cells as treatment for steroid resistant grade II to IV acute GVHD or poor graft function: a multicenter phase II studyEUCTR2007-004310-14-BECHU-ULG120
Withdrawn
Phase 2
Infusion of mesenchymal stem cells as treatment for steroid resistant grade II to IV acute GVHD or poor graft function: a multicenter phase II studymesenchymale stamcellen bij acute GvHD of onvoldoende functionerende greffeacute GvHDrejection1002432410018865NL-OMON31471Academisch Ziekenhuis Maastricht10
Active, not recruiting
Not Applicable
Therapeutic effect of mesenchymal cells in patients suffering from a disease characterized by a severe inflammation and/or in whom the immune system attacks their own tissues.Crohn's diseaseMedDRA version: 14.0Level: LLTClassification code 10011402Term: Crohn's disease (colon)System Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 14.0Level: HLGTClassification code 10003816Term: Autoimmune disordersSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 14.0Level: PTClassification code 10064147Term: Gastrointestinal inflammationSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 14.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2011-005966-39-BECHU-ULg20
Active, not recruiting
Not Applicable
Mesenchymal stem cell based therapy for the treatment of osteogenesis imperfectaOsteogenesis imperfecta (OI) is a rare genetic disorder with increased bone fragility of varying severity. In the majority of patients the disease is caused by mutations in collagen type I. Severe OI is characterized by osteopenia, frequent fractures, progressive deformity, short stature, loss of mobility, chronic pain and can lead to premature death. At present a cure does not exist.Therapeutic area: Body processes [G] - Cell Physiological Phenomena [G04]EUCTR2012-002553-38-ESItziar Astigarraga Aguirre
Active, not recruiting
Not Applicable
Application of Mesenchymal Stem Cells and full of plasma in the management of the burn wound in patients with large burn injury - Stem CellsTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2012-001596-36-ESMIGUEL CASARES FERNÁNDEZ-ALVÉS